Your browser is no longer supported. Please, upgrade your browser.
Settings
CARA Cara Therapeutics, Inc. daily Stock Chart
CARA [NASD]
Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own2.90% Shs Outstand41.97M Perf Week-12.93%
Market Cap664.39M Forward P/E- EPS next Y-2.21 Insider Trans-11.72% Shs Float34.69M Perf Month-19.69%
Income-41.60M PEG- EPS next Q-0.57 Inst Own61.20% Short Float17.10% Perf Quarter-21.56%
Sales7.90M P/S84.10 EPS this Y50.80% Inst Trans22.88% Short Ratio9.47 Perf Half Y-3.12%
Book/sh3.93 P/B4.03 EPS next Y- ROA-50.90% Target Price26.89 Perf Year21.12%
Cash/sh4.91 P/C3.23 EPS next 5Y- ROE-70.80% 52W Range11.46 - 24.30 Perf YTD29.33%
Dividend- P/FCF- EPS past 5Y-29.20% ROI-37.70% 52W High-34.86% Beta2.93
Dividend %- Quick Ratio4.90 Sales past 5Y-5.20% Gross Margin- 52W Low38.13% ATR0.94
Employees37 Current Ratio4.90 Sales Q/Q- Oper. Margin- RSI (14)32.21 Volatility5.91% 5.15%
OptionableYes Debt/Eq0.01 EPS Q/Q-33.60% Profit Margin- Rel Volume1.00 Prev Close16.07
ShortableYes LT Debt/Eq0.01 EarningsNov 06 AMC Payout- Avg Volume626.66K Price15.83
Recom1.60 SMA20-14.11% SMA50-18.44% SMA200-7.55% Volume626,464 Change-1.49%
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Aug-08-16Reiterated Needham Buy $27 → $23
Feb-29-16Reiterated Laidlaw Buy $30 → $17
Nov-04-15Initiated Cantor Fitzgerald Buy
Jul-24-15Reiterated Needham Buy $22 → $27
Mar-03-15Initiated MLV & Co Buy $26
Jan-09-15Initiated Canaccord Genuity Buy $20
Dec-10-18 10:35AM  Alternatives to Watch ACCESSWIRE
Dec-03-18 10:46AM  The Trade War Could Be a Positive Catalyst for Cara Therapeutics Stock InvestorPlace
Dec-02-18 09:17AM  Why Cara Therapeutics Is Up 50% in 2018 Motley Fool
Nov-21-18 11:30AM  Opioid Alternatives Could Make Investors Major Gains ACCESSWIRE
Nov-16-18 09:00AM  12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure Benzinga
Nov-12-18 08:20AM  Research Report Identifies DXP Enterprises, Diebold Nixdorf, Fitbit, Nevro, Plains All American Pipeline, and Cara Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-10-18 09:27AM  Edited Transcript of CARA earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-08-18 04:01PM  Cara Therapeutics to Present at November Investor Conferences GlobeNewswire
Nov-06-18 06:00PM  Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:57PM  Cara: 3Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 08:53AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Nov-01-18 12:20PM  Cannabis and Biotech Stocks That Could Bounce ACCESSWIRE +5.71%
Oct-30-18 04:01PM  Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018 GlobeNewswire
Oct-28-18 06:33AM  Better Buy: Cara Therapeutics, Inc. vs. Scotts Miracle-Gro Company Motley Fool
Oct-23-18 10:09AM  Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In? Investopedia
07:00AM  Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer GlobeNewswire
Oct-19-18 02:00PM  9 Marijuana Stocks to Play the Pot Craze InvestorPlace
Oct-18-18 08:55AM  Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD Discovering Underlying Factors of Influence GlobeNewswire
Oct-10-18 01:31PM  Here's Why Cara Therapeutics Rose 18.7% in September Motley Fool -5.30%
Oct-07-18 06:31AM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Sep-26-18 04:01PM  Cara Therapeutics to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-21-18 03:32PM  Cantor Fitzgerald's 7 Buys For 7 Biotechs Benzinga
Sep-19-18 10:30AM  CBD Stocks Set to Explode ACCESSWIRE
08:00AM  Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Cara Therapeutics ACCESSWIRE
Sep-14-18 01:05PM  Major Stem Cell Breakthroughs Giving Investors Big Opportunity ACCESSWIRE
Sep-13-18 11:55AM  Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate Benzinga
08:45AM  Better Buy: Cara Therapeutics Inc. vs. Fresenius Medical Care AG & Co. Motley Fool
Sep-05-18 04:01PM  Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress GlobeNewswire
01:26AM  Here's Why Cara Therapeutics Rose 12.5% in August Motley Fool
Aug-27-18 07:40AM  Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-22-18 03:40AM  Edited Transcript of CARA earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-19-18 06:33AM  3 Reasons Cara Therapeutics Is a Great Pick for Aggressive Investors Motley Fool
Aug-13-18 01:45PM  4 Cannabis Stocks In Uptrends This Week Benzinga
Aug-08-18 05:35PM  Biotech and Cannabis Companies Set to Own The Future ACCESSWIRE +5.23%
Aug-07-18 06:30PM  Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:26PM  Cara: 2Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
07:00AM  Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus GlobeNewswire
Aug-06-18 07:00AM  Cara Therapeutics Appoints Christopher A. Posner to Board of Directors GlobeNewswire
Jul-31-18 04:05PM  Cara Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-27-18 07:35AM  Initiating Free Research Reports on Celgene and Three Other Biotech Equities ACCESSWIRE
Jul-25-18 07:30AM  This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up ACCESSWIRE
Jul-23-18 04:02PM  Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 08:00AM  Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA PR Newswire
Jul-18-18 08:53PM  Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock GlobeNewswire -8.24%
04:50PM  What Happened in the Stock Market Today Motley Fool
08:20AM  Today's Research Reports on Trending Tickers: Cara Therapeutics and Cellectar Biosciences ACCESSWIRE
Jul-17-18 04:23PM  Cara Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
02:22PM  The Picture for Cara Therapeutics Just Got Clearer Motley Fool
Jul-15-18 05:02PM  Here's Why Cara Therapeutics Jumped 56.5% in the First Half of 2018 Motley Fool
Jul-11-18 07:00AM  Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients GlobeNewswire
Jul-06-18 07:12PM  Cramer's lightning round: Buy Merck on its superior anti-... CNBC Videos
06:48PM  Cramer's lightning round: Buy Merck on its superior anti-cancer portfolio CNBC
Jul-05-18 06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
Jul-04-18 09:21AM  The Best Marijuana Stocks in the Second Quarter Motley Fool
Jul-01-18 07:17AM  Is Cara Therapeutics, Inc. a Buy? Motley Fool
Jun-28-18 09:42AM  Needham Incrementally Bullish On Cara Therapeutics After CR845 Meets Endpoints Benzinga +6.70%
09:31AM  Does Post-Op Success Make Cara Therapeutics a Buy Now? Motley Fool
08:10AM  Today's Research Reports on Trending Tickers: Global Blood Therapeutics and Cara Therapeutics ACCESSWIRE
Jun-27-18 04:49PM  What Happened in the Stock Market Today Motley Fool +9.85%
04:31PM  Concho Resources, CMS Energy climb while Conagra stumbles Associated Press
01:59PM  Why Cara Therapeutics Stock Is Soaring Today InvestorPlace
01:16PM  Why Cara Therapeutics Inc. Stock Soared Today Motley Fool
09:29AM  Cara Therapeutics Rallies On Positive Opioid Receptor Agonist Trial Results Benzinga
09:05AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery GlobeNewswire
Jun-21-18 11:19AM  Drugs from Heron Therapeutics and two other biotech companies can boost your investment returns by reducing opioid abuse MarketWatch
08:00AM  Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks ACCESSWIRE
07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Camden National, Cara Therapeutics, Albany International, Emerge Energy Services LP, Fiesta Restaurant Group, and Resources Connection New Research Emphasizes Economic Growth GlobeNewswire
Jun-19-18 08:51AM  Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options Zacks
Jun-14-18 12:49PM  Here's Why Cara Therapeutics Jumped 26.3% in May Motley Fool
Jun-10-18 07:17AM  Better Marijuana Stock: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Jun-07-18 03:00PM  Where Will Cara Therapeutics, Inc. Be in 5 Years? Motley Fool
May-30-18 08:26AM  Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod Zacks
May-29-18 04:30PM  Cara Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire -6.93%
May-25-18 03:57PM  Why Cara Therapeutics Shares Jumped 10% Today Motley Fool +9.38%
06:04AM  Does This New Partnership Make Cara Therapeutics Stock a Buy Now? Motley Fool
May-24-18 02:50PM  NYSE trader: Cannabis stocks are migrating from Canada to the USa trend here to stay Yahoo Finance Video -6.04%
08:00AM  Todays Research Reports on Stocks to Watch: Avinger and Cara Therapeutics ACCESSWIRE
06:34AM  Why Wall Street Analysts Think This Biotech Stock Could Nearly Double Motley Fool
May-23-18 11:35AM  Cara Therapeutics Shares Jump On Licensing Deal For Pruritis Treatment Benzinga +42.76%
09:02AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:35AM  Investors Are Undervaluing Cara Therapeutics Inc (NASDAQ:CARA) By 26% Simply Wall St.
08:10AM  Why Cara Therapeutics' Stock Is Popping Today Motley Fool
06:00AM  Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA Injection in Dialysis Patients with Pruritus GlobeNewswire
May-18-18 04:22AM  Edited Transcript of CARA earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-17-18 12:55PM  Forget Cara Therapeutics' Earnings -- Here's the Real News Motley Fool
May-14-18 04:01PM  Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting GlobeNewswire
May-10-18 09:44AM  Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results Benzinga -6.84%
May-09-18 04:53PM  Cara: 1Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 04:30PM  Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018 GlobeNewswire
12:19PM  Edited Transcript of CARA earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
Apr-30-18 08:15AM  Research Report Identifies Cara Therapeutics, MGE Energy, IDEXX Laboratories, Sterling Construction, TTM Technologies, and Regis with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-20-18 10:54AM  4/20: Marijuana, hemp legalization moves ahead in many states Yahoo Finance Video
08:03AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Apr-10-18 07:00AM  Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation GlobeNewswire
Apr-06-18 01:43PM  Here's Why Cara Therapeutics Slipped 11.4% in March Motley Fool
Apr-04-18 09:03AM  Should You Be Concerned About Cara Therapeutics Incs (NASDAQ:CARA) Earnings Growth? Simply Wall St.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHALMERS DEREK TPresident & CEODec 03Sale18.1720,000363,400971,392Dec 06 04:16 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentDec 03Sale18.363,00055,080139,000Dec 06 04:18 PM
Mohindru ManiCFO & Chief Strategy OfficerNov 15Option Exercise14.0616,042225,55116,042Nov 16 04:22 PM
Mohindru ManiCFO & Chief Strategy OfficerNov 15Sale18.5016,042296,7770Nov 16 04:22 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentNov 01Option Exercise2.0540,00082,000145,000Nov 05 08:25 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentNov 01Sale18.773,00056,310142,000Nov 05 08:25 PM
CHALMERS DEREK TPresident & CEONov 01Sale18.7820,000375,600991,392Nov 02 05:35 PM
Mohindru ManiCFO & Chief Strategy OfficerOct 17Option Exercise14.0616,042225,55116,042Oct 19 04:32 PM
Stauffer Joseph WilliamChief Medical OfficerOct 17Sale20.1311,442230,3472,000Oct 19 04:34 PM
Mohindru ManiCFO & Chief Strategy OfficerOct 17Sale20.1916,042323,8880Oct 19 04:32 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentOct 01Sale23.993,00071,97095,000Oct 03 04:09 PM
CHALMERS DEREK TPresident & CEOOct 01Sale23.7920,000475,8001,011,392Oct 03 04:08 PM
CHALMERS DEREK TPresident & CEOSep 04Sale19.7120,000394,2001,031,392Sep 06 05:34 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentSep 04Sale19.813,00059,43098,000Sep 06 05:33 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentAug 20Sale18.893,00056,670101,000Aug 22 05:26 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentAug 06Option Exercise2.2510,00022,500114,000Nov 05 08:21 PM
CHALMERS DEREK TPresident & CEOJul 10Sale20.6420,000412,8001,051,392Jul 12 04:42 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentJul 02Sale19.003,00057,000104,000Jul 05 05:00 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentJun 01Sale15.493,00046,470107,000Jun 05 07:15 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentMay 23Sale15.199,000136,710110,000May 25 04:22 PM
CHALMERS DEREK TPresident & CEOFeb 16Sale15.005,40081,0001,071,392Feb 21 05:13 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentFeb 15Sale15.023,00045,060119,000Feb 20 04:43 PM
CHALMERS DEREK TPresident & CEOJan 25Option Exercise6.003,00018,0001,076,792Jan 26 05:52 PM
CHALMERS DEREK TPresident & CEOJan 24Sale15.0012,500187,5001,073,792Jan 26 05:52 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentJan 24Sale15.0015,000225,000122,000Jan 26 05:53 PM